Carmell Corporation

Equities

CTCX

US1429221039

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 31/05/2024 BST 5-day change 1st Jan Change
2.49 USD +1.63% Intraday chart for Carmell Corporation -3.11% -34.65%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Carmell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Carmell Corporation announced that it has received $3 million in funding CI
Carmell Corporation announced that it expects to receive $3 million in funding CI
Carmell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
An undisclosed buyer completed the acquisition of Axolotl Biologix, Inc. from Carmell Corporation. CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Fed Maintains Rate Cut Outlook MT
Carmell Sells Axolotl Biologix Unit -- Shares Jump Premarket MT
An undisclosed buyer entered into a a definitive agreement to acquire Axolotl Biologix, Inc. from Carmell Corporation ). CI
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024 CI
Carmell Corporation Announces Appointment of Dr. Bradley Calobrace to Scientific Advisory Board CI
Carmell Corp Announces Appointment of Dr. Jason D. Bloom to Scientific Advisory Board CI
Carmell Corporation Announces Appointment of Dr. Adam Rubinstein to Scientific Advisory Board CI
Carmell Corporation Announces Appointment of Dr. Gregory A. Buford to Scientific Advisory Board CI
Carmell Corporation Announces Appointment of Dr. Sean Kelishadi to Scientific Advisory Board CI
Carmell Corporation Announces Addition of Two Independent Directors CI
Carmell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Carmell Therapeutics Corporation(NasdaqCM:CTCX) added to S&P TMI Index CI
Carmell Corporation Announces Board Changes CI
Carmell Corporation Announces CEO Changes CI
Carmell Closes Axolotl Biologix Merger MT
Carmell Therapeutics Corporation completed the acquisition of Axolotl Biologix, Inc. CI
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading MT
Strong GDP Growth, Meta Platforms' Earnings Fuel Premarket Gains for US Equity Futures MT
Top Premarket Gainers MT
Carmell Therapeutics Corporation entered into a definitive agreement to acquire Axolotl Biologix, Inc. CI
Chart Carmell Corporation
More charts
Carmell Corporation (Carmell) is a bio-aesthetics company focused on skin and hair health. The Company utilizes the Carmell Secretome to support skin and hair health. The Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from United States Food and Drug Administration-approved tissue banks. The Company has developed a novel micellar nanoparticle formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the harmful excipients that are used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell’s micellar formulations do not utilize mineral or vegetable oils across their entire product line and are designed to be non-comedogenic. The Company is also developing a line of men’s products and a line of topical haircare products.
More about the company
  1. Stock Market
  2. Equities
  3. CTCX Stock
  4. News Carmell Corporation
  5. Carmell Sells Axolotl Biologix Unit -- Shares Jump Premarket